PACTG 1025: PERINATAL CORE PROTOCOL (AIDS)

PACTG 1025：围产期核心方案（艾滋病）

• 批准号: 7378274
• 负责人: William Borkowsky
• 金额: $ 14.21万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7378274
• 关键词: PACTG; 1025; PERINATAL; CORE; PROTOCOL

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The efficacy of antiretroviral therapy in preventing vertical transmission of HIV is undisputed. The investigators note, however, that a small percentage of children born to HIV-infected mothers are infected. Doing a controlled study in this population is unethical. Thus the PACTG will follow approximately 2400 mother/infant pairs who will be treated at PACTG sites and determine which children become infected, to which drug regimens their mothers were prescribed, how difficult it was to follow the regimen and how closely they adhered to it. They will compare efficacy of interventions prescribed, safety of interventions prescribed and adherence to antiretroviral therapy by HIV-infected pregnant women and its impact on vertical transmission. They will also establish a repository for specimens for future studies to evaluate risk factors and outcomes. They hypothesize that adherence will be better during pregnancy than post-partum; more complex regimens will have poorer adherence; toxicity will give poorer adherence. This study will help evaluate issues in treating pregnant women with HIV. Many are already enrolled in treatment studies. Uniformity of data collection and determination of fetal outcomes will provide much needed information regarding best treatment during pregnancy. Enrollment has begun and is continuing on this multicenter trial.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中得到体现。列出的机构是中心的机构，不一定是研究者的机构。抗逆转录病毒治疗在预防艾滋病毒垂直传播方面的功效是无可争议的。然而，调查人员指出，感染艾滋病毒的母亲所生的孩子中有一小部分受到感染。在这一人群中进行对照研究是不道德的。因此，PACTG 将跟踪大约 2400 对将在 PACTG 地点接受治疗的母婴对，并确定哪些儿童被感染、他们的母亲接受了哪些药物治疗方案、遵循该治疗方案的难度以及他们遵守该治疗方案的程度。他们将比较所规定的干预措施的有效性、所规定的干预措施的安全性以及艾滋病毒感染孕妇对抗逆转录病毒治疗的依从性及其对垂直传播的影响。他们还将建立一个样本库，供未来研究评估风险因素和结果。他们假设怀孕期间的依从性会比产后更好。治疗方案越复杂，依从性就越差；毒性会导致依从性较差。这项研究将有助于评估治疗感染艾滋病毒的孕妇的问题。许多人已经参加了治疗研究。数据收集和胎儿结局确定的一致性将为怀孕期间最佳治疗提供急需的信息。这项多中心试验的招募工作已经开始，并将继续进行。